Sign In
Buy ZLAB
$17.17
+0.0200 (+0.117%)
At Close: Jun 03, 2026
Zai Lab Limited: A Best Price-Positioned Biotech Stock, As Seen By Market-Makers
12:50am, Sunday, 07'th Nov 2021
Zai Lab Limited: A Best Price-Positioned Biotech Stock, As Seen By Market-Makers
Zai Lab Posts Encouraging Data From Early-Stage Plaque Psoriasis Trial
06:11am, Thursday, 21'st Oct 2021
Zai Lab Limited (NASDAQ: ZLAB) announced topline results from Phase 1b study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP). ZL-1102 is an invest
Zai Lab Appoints Scott Morrison to its Board of Directors
07:30am, Monday, 18'th Oct 2021
SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical
Zai Lab Announces Upcoming Presentations in October Investor Conferences
07:30am, Monday, 11'th Oct 2021
SHANGHAI and SAN FRANCISCO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that
SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) partner Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company de
Final data collection is expected in the first half of 2022
Zai Lab Holds Virtual Research and Development Day
12:22pm, Wednesday, 22'nd Sep 2021
-- Expects to have more than 15 marketed products in more than 35 indications by 2025-- Aspires to become a leading global biopharmaceutical company
Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community
07:30am, Thursday, 16'th Sep 2021
SHANGHAI and SAN FRANCISCO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, announced today that it will expa
Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China
07:30am, Tuesday, 14'th Sep 2021
Potential first-in-class therapy for a subset of gastric and gastroesophageal (GEJ) cancers that overexpress fibroblast growth factor receptor 2 (FGFR2b) Potential first-in-class therapy for a subset
Zai Lab Announces Upcoming Presentations in September Investor Conferences
07:30am, Tuesday, 24'th Aug 2021
SHANGHAI and SAN FRANCISCO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that
Zai Lab Limited (ZLAB) CEO Samantha Du on Q2 2021 Results - Earnings Call Transcript
01:58pm, Tuesday, 10'th Aug 2021
Zai Lab Limited (ZLAB) CEO Samantha Du on Q2 2021 Results - Earnings Call Transcript
Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates
04:30pm, Monday, 09'th Aug 2021
Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT
Schrödinger, Zai Lab Team Up For Cancer Program Targeting DNA Damage Response
11:53am, Wednesday, 04'th Aug 2021
Schrödinger Inc (NASDAQ: SDGR) and Zai Lab Limited (NASDAQ: ZLAB) have collaborated to discover, develop, and commercialize oncology candidate targeting DNA damage response. The research program
Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology
07:30am, Wednesday, 04'th Aug 2021
Agreement provides Schrödinger and Zai Lab with pipeline expansion opportunities in precision oncology Agreement provides Schrödinger and Zai Lab with pipeline expansion opportunities in precision o
Reviewing Our Recent Zai Lab Limited Buy Recommendation
09:03pm, Friday, 30'th Jul 2021
As noted in Wall Street Breakfast "Even when you think China risk is priced, it can get worse" Recent Government actions prompt a new degree of caution in further advices; should we go to the point of
